The Discounted Cash Flow (DCF) valuation of Hyloris Pharmaceuticals SA (HYL.BR) is (612.65) EUR. With the latest stock price at 6.88 EUR, the upside of Hyloris Pharmaceuticals SA based on DCF is -9004.7%.
Based on the latest price of 6.88 EUR and our DCF valuation, Hyloris Pharmaceuticals SA (HYL.BR) is a sell. selling HYL.BR stocks now will result in a potential gain of 9004.7%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.1% - 6.7% | 5.9% |
| Long-term Growth Rate | 3.0% - 4.8% | 3.9% |
| Fair Price | (4,749.87) - (329.70) | (612.65) |
| Upside | -69138.8% - -4892.1% | -9004.7% |